LDFR
CRSP icon

Lehman & Derafelo Financial Resources’s CRISPR Therapeutics CRSP Stock Holding History

Lehman & Derafelo Financial Resources’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-50
Closed -$4K – 273
2020
Q2 		$4K Buy
+50
New +$2.92K ﹤0.01% 236

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Lehman & Derafelo Financial Resources's CRSP Position: Q3 2020 in Review

Lehman & Derafelo Financial Resources sold out of CRISPR Therapeutics (CRSP) in Q3 2020, closing a stake of 50 shares — an estimated $4K sold.

Lehman & Derafelo Financial Resources first reported a position in CRSP in Q2 2020 and held it in 1 quarter. The position peaked at $4K in Q2 2020. 310 funds tracked by Wall St. Rank hold CRSP as of Q3 2020.

  • Lehman & Derafelo Financial Resources reported no remaining CRISPR Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Lehman & Derafelo Financial Resources sold 50 CRISPR Therapeutics shares in Q3 2020, an estimated $4K.
  • Lehman & Derafelo Financial Resources first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 1 quarter.
  • Lehman & Derafelo Financial Resources's CRISPR Therapeutics position peaked at $4K in Q2 2020.
  • 310 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2020.

Based on Lehman & Derafelo Financial Resources's 13F filing for Q3 2020, filed 6 Nov 2020.